A Phase 3 interventional study of Comparator: rosuvastatin 5 mg + ezetimibe 10 mg and Comparator: rosuvastatin 10 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 21st largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2008, is one of 33 in phase 3, and was the 29th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 31st largest by enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2008, is one of 58 in phase 3, and was the 69th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of the addition of ezetimibe to rosuvastatin compared with doubling dose of rosuvastatin in participants treated with rosuvastatin alone and not at their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg
Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
Drug: Comparator: rosuvastatin 10 mg
Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg
Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Drug: Comparator: rosuvastatin 20 mg
Drug page: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
Also known as: Crestor, Zetia
Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
Also known as: Crestor
Drug page: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
Also known as: Crestor, Zetia
Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Also known as: Crestor
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment
The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment in participants who were administered ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
Time frame: Baseline to 6 weeks
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum
The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment by stratum I and stratum II in participants who were administered with ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with the doubling of the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
Time frame: Baseline to 6 weeks
Number of Participants Who Reached Their Target LDL-C Level
Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment.
Time frame: 6 weeks of treatment
Number of Participants in Each Stratum Who Reached Their Target LDL-C Level
Participants in stratum I were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 5 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 10 mg daily for 6 weeks. Participants in stratum II were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 10 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 20 mg daily for 6 weeks.
Time frame: 6 weeks of treatment
Number of Participants Who Reached the LDL-C Level of <70 mg/dl
Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
Time frame: 6 weeks of treatment
Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl
Participants in stratum I and in stratum II who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe to rosuvastatin (5 or 10 mg)daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg).
Time frame: 6 weeks of treatment
Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels
Participants who were analyzed to assess the Total Cholesterol (TC), Triglycerides, High-Density Lipoprotein Cholesterol, Non High-Density Lipoprotein Cholesterol, LDL Cholesterol/HDL Cholesterol, Total Cholesterol/HDL Cholesterol, Non-HDL Cholesterol/HDL Cholesterol, Apolipoprotein B (Apo B), Apolipoprotein A-I (Apo A-I), Apolipoprotein B/Apo A-I, high-sensitivity C-reactive protein (hs-CRP)levels after 6 weeks of treatment.
Time frame: Baseline to 6 weeks
| Milestone | Rosuvastatin 5 mg + Ezetimibe 10 mg | Rosuvastatin 10 mg | Rosuvastatin 10 mg + Ezetimibe 10 mg | Rosuvastatin 20 mg |
|---|---|---|---|---|
| Started | 99 | 98 | 122 | 121 |
| Completed | 95 | 96 | 119 | 118 |
| Not completed | 4 | 2 | 3 | 3 |
| Withdrew: Adverse event | 3 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 |
The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment in participants who were administered ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
| percent change | Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Rosuvastatin (10 or 20 mg) |
|---|---|---|
| Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment | -21.57 ± 25.09 | -5.58 ± 25.42 |
The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment by stratum I and stratum II in participants who were administered with ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with the doubling of the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
| percentage change | Rosuvastatin 5 mg + Ezetimibe 10 mg (Stratum I) | Rosuvastatin 10 mg (Stratum I) | Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) | Rosuvastatin 20 mg (Stratum II) |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum | -18.57 ± 26.35 | -4.96 ± 22.42 | -24.00 ± 23.86 | -6.07 ± 27.65 |
Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment.
| participants | Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Rosuvastatin (10 or 20 mg) |
|---|---|---|
| Number of Participants Who Reached Their Target LDL-C Level | 130 | 67 |
Participants in stratum I were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 5 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 10 mg daily for 6 weeks. Participants in stratum II were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 10 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 20 mg daily for 6 weeks.
| participants | Rosuvastatin 5 mg + Ezetimibe 10 mg (Stratum I) | Rosuvastatin 10 mg (Stratum I) | Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) | Rosuvastatin 20 mg (Stratum II) |
|---|---|---|---|---|
| Number of Participants in Each Stratum Who Reached Their Target LDL-C Level | 54 | 30 | 76 | 37 |
Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
| participants | Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Rosuvastatin 10 or 20 mg |
|---|---|---|
| Number of Participants Who Reached the LDL-C Level of <70 mg/dl | 96 | 38 |
Participants in stratum I and in stratum II who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe to rosuvastatin (5 or 10 mg)daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg).
| participants | Rosuvastatin 5 mg + Ezetimibe 10 mg | Rosuvastatin 10 mg | Rosuvastatin 10 mg + Ezetimibe 10 mg | Rosuvastatin 20 mg |
|---|---|---|---|---|
| Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl | 31 | 12 | 65 | 26 |
Participants who were analyzed to assess the Total Cholesterol (TC), Triglycerides, High-Density Lipoprotein Cholesterol, Non High-Density Lipoprotein Cholesterol, LDL Cholesterol/HDL Cholesterol, Total Cholesterol/HDL Cholesterol, Non-HDL Cholesterol/HDL Cholesterol, Apolipoprotein B (Apo B), Apolipoprotein A-I (Apo A-I), Apolipoprotein B/Apo A-I, high-sensitivity C-reactive protein (hs-CRP)levels after 6 weeks of treatment.
| percentage change | Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Rosuvastatin 10 or 20 mg |
|---|---|---|
| Total Cholesterol (TC) | -13.00 ± 17.51 | -3.76 ± 14.35 |
| Triglycerides | -5.96 ± 36.45 | -3.60 ± 32.83 |
| High-Density Lipoprotein Cholesterol | -0.67 ± 15.51 | 2.18 ± 13.38 |
| Non High-Density Liproprotein Cholesterol | -17.59 ± 23.55 | -5.29 ± 21.20 |
| LDL Cholesterol/HDL Cholesterol | -19.48 ± 27.63 | -6.18 ± 27.82 |
| Total Cholesterol/HDL Cholesterol | -10.57 ± 25.87 | -4.40 ± 18.27 |
| Non-HDL Cholestrol/HDL Cholesterol | -14.51 ± 35.39 | -5.31 ± 26.63 |
| Apolipoprotein B (Apo B) | -14.31 ± 18.61 | -4.25 ± 17.56 |
| Apolipoprotein A-I (Apo A-I) | -1.44 ± 12.49 | 1.06 ± 11.56 |
| Apolipoprotein B/Apo A-I | -11.98 ± 20.84 | -4.11 ± 19.61 |
| hs-C-Reactive Protein | -13.98 ± 72.19 | -12.82 ± 73.08 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuva 5 mg + EZ 10 mg | — | 0/99 (0%) | 0/99 (0%) |
| Rosuva 10 mg | — | 1/98 (1%) | 0/98 (0%) |
| Rosuva 10 mg + EZ 10 mg | — | 0/122 (0%) | 0/122 (0%) |
| Rosuva 20 mg | — | 1/121 (0.8%) | 0/121 (0%) |
| Event | Rosuva 5 mg + EZ 10 mg | Rosuva 10 mg | Rosuva 10 mg + EZ 10 mg | Rosuva 20 mg |
|---|---|---|---|---|
| Tendon ruptureInjury, poisoning and procedural complications | 0/99 | 1/98 | 0/122 | 0/121 |
| Sick sinus syndromeCardiac disorders | 0/99 | 0/98 | 0/122 | 1/121 |
| Age, Customized(participants) | Rosuvastatin 5 mg + Ezetimibe 10 mg | Rosuvastatin 10 mg | Rosuvastatin 10 mg + Ezetimibe 10 mg | Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|
| < 65 years | 63 | 62 | 71 | 71 | 267 |
| ≥ 65 years | 36 | 36 | 51 | 50 | 173 |
| Sex: Female, Male(Participants) | Rosuvastatin 5 mg + Ezetimibe 10 mg | Rosuvastatin 10 mg | Rosuvastatin 10 mg + Ezetimibe 10 mg | Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|
| Female | 35 | 40 | 56 | 37 | 168 |
| Male | 64 | 58 | 66 | 84 | 272 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Nov 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 4 months after primary completion. A results delay was requested in May 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin